<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58721">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01912534</url>
  </required_header>
  <id_info>
    <org_study_id>VANISH</org_study_id>
    <secondary_id>5P50HL112349</secondary_id>
    <nct_id>NCT01912534</nct_id>
  </id_info>
  <brief_title>Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM</brief_title>
  <acronym>VANISH</acronym>
  <official_title>Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine whether treatment with valsartan will have
      beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that
      reflect myocardial structure, function and biochemistry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, double-blind, placebo-controlled Phase II, randomized clinical trial
      to assess the safety and efficacy of valsartan in attenuating disease evolution in early
      HCM.  Sarcomere mutation carriers with asymptomatic or mildly symptomatic overt disease
      (NYHA class I-II), and mutation carriers without left ventricular hypertrophy (LVH) will be
      studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A combined single composite z-score (described below) will serve as primary surrogate endpoint to monitor response to valsartan treatment</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Myocardial injury, hemodynamic stress, collagen metabolism, functional capacity, myocardial fibrosis, cardiac morphology, and cardiac function endpoints will be combined into a single composite z-score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of valsartan treatment on disease pathology</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in, stability of, or attenuation of progression in 7 components of primary composite outcomes; left atrial size; assessment of left ventricle (LV) mass by cardiac magnetic resonance imaging(CMR); LV systolic and diastolic function; the degree of interstitial myocardial fibrosis as assessed by novel CMR sequences; additional parameters from metabolic exercise testing and additional serum biomarkers that reflect fibrosis, injury and stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes and assessment of symptom burden</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Specifically, decline 1 point on NYHA or increase in therapy for HCM; development of arrhythmias; time to development of HCM-related symptoms; development of obstructive physiology; development of a new murmur; activity level as tracked by activity monitor and survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse drug reactions, frequency of subject drop-out, and responses to validated quality of life metrics between valsartan and placebo-treated group</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of adverse drug reactions, frequency of subject drop-out, and responses to validated quality of life metrics between valsartan and placebo-treated group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During active run-in, all subjects will be started on valsartan at an initial dose of 40 mg twice daily (20 mg twice daily in children ≤16 years old, or adults with baseline systolic BP&lt;100 mmHg).  This initial dose will be received through the mail within 2 weeks of Visit 1 and titration will begin after communication with the study coordinator confirming that trial eligibility criteria were met.  Valsartan dose will be titrated at 2-week intervals to a target dose of 320 mg/day in adults; 160 mg/day in children ≥35 kg; 80 mg/day in children &lt;35 kg.
Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group.  Treatment will continue for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During active run-in, all subjects will be started on valsartan at an initial dose of 40 mg twice daily (20 mg twice daily in children ≤16 years old, or adults with baseline systolic BP&lt;100 mmHg).  This initial dose will be received through the mail within 2 weeks of Visit 1 and titration will begin after communication with the study coordinator confirming that trial eligibility criteria were met.  Valsartan dose will be titrated at 2-week intervals to a target dose of 320 mg/day in adults; 160 mg/day in children ≥35 kg; 80 mg/day in children &lt;35 kg.
Subjects who tolerate active run-in and titration to target dose of valsartan will then undergo stratified randomization and begin blinded treatment with valsartan or matched placebo on maximal tolerated dose, according to their assigned treatment group.  Treatment will continue for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>40, 80 and 160 mg tablets of Valsartan</description>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>During Active Run-In, all patients take Valsartan.  During maintenance, all patients are randomized to valsartan or placebo</description>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo pills manufactured to match Valsartan 160 mg, 80 mg, 40 mg tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must have a Pathogenic or Likely Pathogenic HCM Sarcomere Mutation

          -  The following categories of mutations are considered acceptable for subjects who have
             previously undergone clinical genetic testing.  If results are ambiguous, they will
             be reviewed by the Clinical Coordinating Center to determine eligibility.

               1. Laboratory for Molecular Medicine (Pathogenic, Likely Pathogenic)

               2. Transgenomics/ PGXHealth (Class I)

               3. GeneDx (Disease causing; Variant; likely disease-causing; Published,
                  disease-causing mutation; Novel, likely disease-causing, mutation)

               4. Correlagen (Associated; Probably Associated

        Overt HCM Cohort

          -  LV wall thickness ≥12 mm and &lt; 20 mm (in subjects ≥18 years) or z score ≥3 and &lt; 10
             as determined by rapid assessment by the echocardiographic core laboratory

          -  NYHA functional class I or II; no perceived or only slight limitations in physical
             activities

          -  No resting or provokable LV obstruction (peak gradient ≤ 30 mmHg) on
             clinically-obtained Exercise Tolerance Test (ETT)-echo within the past 24 months or
             transthoracic echo with Valsalva maneuver within the past 12 months

          -  Age 8-30 years

          -  Able to attend follow-up appointments, complete all study assessments, and provide
             written informed consent

        Preclinical HCM Cohort (G+/LVH-)

          -  LV Wall Thickness &lt;12 mm (in subjects ≥18 years) or z score &lt;3 (in subjects &lt;18
             years), as determined by rapid assessment by the echocardiographic core laboratory

          -  Age 10-25 years

          -  E' z score ≤ -2 OR  ECG abnormalities other than Non-specific ST or T-wave
             abnormalities (NSSTW) changes (Q waves, T wave inversion, repolarization changes)

          -  Able to attend follow-up appointments, complete all study assessments, and provide
             written informed consent

        Subject Exclusion Criteria

          -  Contraindication to angiotensin receptor blocker (ARB) administration, including
             impaired renal function, hyperkalemia (serum K&gt;5.0 mmol/L), prior history of
             angioedema

          -  Medical conditions associated with increased collagen turnover that may confound
             interpretation of biomarkers of collagen synthesis (liver, pulmonary or renal
             fibrosis, inflammatory states, cancer, trauma or surgery within 6 months of
             enrollment)

          -  Concomitant or prior use of ARB or ACE-inhibitors

          -  Pregnant or breastfeeding females

          -  Females of childbearing potential with no effective contraceptive method (including
             abstinence)

          -  Systemic Hypertension (HTN) (Systolic Blood Pressure (SBP) &gt;140 and/or Diastolic
             Blood Pressure (DBP) &gt;90), or on medical therapy for HTN

          -  Obstructive physiology, defined by resting, Valsalva-provoked or exercise-induced
             gradient &gt;30 mm Hg within the past 24 months

          -  Prior septal myectomy or alcohol septal ablation

          -  Known, suspected, or symptomatic coronary artery disease or evidence of prior
             myocardial infarction based on symptoms or cardiac imaging

          -  More than mild valvular heart disease or congenital heart disease (allowable
             conditions include bicuspid aortic valve without stenosis or regurgitation;
             spontaneously closed ventricular septal defects; patent foramen ovale, small
             (&lt;/=2mm) restrictive ventricular septal defects with normal ventricular size, and
             other minor defects that are considered allowable after review and consensus by the
             echo core lab, participating pediatric cardiologists, and overall study PI)

          -  Left ventricular ejection fraction (LVEF) &lt;55%

          -  Concomitant medical conditions that would preclude performance of or confound
             interpretation of echocardiography, exercise testing, or CMR (eg, renal
             insufficiency, lung disease, orthopedic/rheumatologic conditions, implantable
             cardioverter-defibrillator (ICD) or pacemaker, atrial fibrillation)

          -  Prior treatment or hospitalization for symptomatic heart failure

          -  Participation in a clinical trial (except observational studies) involving
             investigational medications within the previous 30 days.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Y. Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Euan Ashley, MD, PhD</last_name>
      <phone>650-498-4900</phone>
      <email>euan@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Euan Ashley, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthew Taylor, MD, PhD</last_name>
      <phone>303-724-1400</phone>
      <email>matthew.taylor@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Taylor, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luisa Mestroni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth McNally, MD</last_name>
      <phone>773-702-2672</phone>
      <email>emcnally@uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth McNally, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Murphy, MD</last_name>
      <phone>410-955-5987</phone>
      <email>murphy@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Murphy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ted Abraham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Ho, MD</last_name>
      <phone>617-732-5685</phone>
      <email>cho@partners.org</email>
    </contact>
    <investigator>
      <last_name>Carolyn Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark A. Fifer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Colan, MD</last_name>
      <phone>617-355-7893</phone>
      <email>colan@alum.mit.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Colan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renee Margosian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharlene Day, MD</last_name>
      <phone>734-615-7917</phone>
      <email>sday@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Sharlene Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Russell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Canter, MD</last_name>
      <phone>314-454-6095</phone>
      <email>canter@kids.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Canter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Keith Mankovitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cinncinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cinncinati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Towbin, MD</last_name>
      <phone>513-636-3049</phone>
      <email>jeffrey.towbin@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Towbin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Lynn Jeffries, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry Lever, MD</last_name>
      <phone>216-444-6970</phone>
      <email>leverh@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Harry Lever, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Zahka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas DiSalvo, MD</last_name>
      <phone>615-322-2318</phone>
      <email>thomas.g.disalvo@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas DiSalvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Becker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Larry Markham, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lee Benson, MD</last_name>
      <phone>416-813-6141</phone>
      <email>lee.benson@sickkids.ca</email>
    </contact>
    <investigator>
      <last_name>Lee Benson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W3S5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry Rakowski, MD</last_name>
      <phone>416-340-4062</phone>
      <email>harry.rakowski@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Harry Rakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>April 16, 2014</lastchanged_date>
  <firstreceived_date>June 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcomere Mutations</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
